sodium-glucose cotransporter-2 inhibitor (SGLT2i)
Showing 1 - 25 of >10,000
Sleep Apnea Trial in New Haven, Cleveland (Ertugliflozin 15 mg, Placebo)
Not yet recruiting
- Sleep Apnea
- Ertugliflozin 15 mg
- Placebo
-
New Haven, Connecticut
- +1 more
Jan 24, 2023
Heart Failure With Reduced Ejection Fraction Trial in Porto (Sacubitril-valsartan, SGLT2 inhibitor)
Recruiting
- Heart Failure With Reduced Ejection Fraction
- Sacubitril-valsartan
- SGLT2 inhibitor
-
Porto, Portugal
- +3 more
Aug 9, 2023
Fatty Liver, Nonalcoholic Trial (SGLT2 inhibitor)
Not yet recruiting
- Fatty Liver, Nonalcoholic
- SGLT2 inhibitor
- (no location specified)
Oct 31, 2023
Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral
Not yet recruiting
- Acute Kidney Injury
- +2 more
- Dapagliflozin 10 MG Oral Tablet [Farxiga]
- Placebo
-
Amsterdam, Netherlands
- +5 more
Oct 18, 2022
Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular
Not yet recruiting
- SGLT2 Inhibitiors Remodeling Effect
- Chronic Heart Disease
- Sodium-glucose cotransporter 2 inhibitor
- (no location specified)
Nov 14, 2023
Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)
Not yet recruiting
- Diabetes Mellitus
- +2 more
- SGLT2 inhibitor
- Glimepiride
-
Seoul, Korea, Republic ofYonsei University College of Medicine
Aug 1, 2023
SGLT2 Inhibition in Heart Failure
Recruiting
- Heart Failure
- Sodium-glucose cotransporter 2 inhibitor
-
Belfast, United KingdomBelfast Health and Social Care Trust
Nov 15, 2023
Cardiorenal Syndrome Trial in New Haven (Dapagliflozin)
Not yet recruiting
- Cardiorenal Syndrome
-
New Haven, ConnecticutYale New Haven Hospital
Oct 26, 2023
Tricuspid Regurgitation Trial in Seoul (Dapagliflozin Propanediol Hydrate 12.3 mg)
Recruiting
- Tricuspid Regurgitation
- Dapagliflozin Propanediol Hydrate 12.3 mg
-
Seoul, Korea, Republic ofSamsung Medical Center
Jan 9, 2023
(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in
Not yet recruiting
- Diabetes Mellitus, Type 2
- Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
- (no location specified)
May 22, 2023
MDD Trial in New York (Empagliflozin)
Not yet recruiting
- Major Depressive Disorder
-
New York, New YorkNYU Langone Health
Feb 24, 2023
Cystinuria Trial in San Francisco (Dapagliflozin)
Not yet recruiting
- Cystinuria
-
San Francisco, CaliforniaUniversity of California, San Francisco
Sep 13, 2022
Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan
Recruiting
- Heart Failure
- +2 more
- SGLT2 inhibitor
-
Roma, RM, ItalyFondazione Policlinico Universitario A. Gemelli IRCSS
Jun 28, 2023
SGLT-2 Inhibitors in the Treatment of Ascites
Recruiting
- Ascites Hepatic
- +2 more
- SGLT2 inhibitor
-
Palermo, Italy
- +1 more
Aug 11, 2023
IgA Nephropathy, Immunoglobulin A Nephropathy Trial (Atrasentan, Placebo)
Not yet recruiting
- IgA Nephropathy
- Immunoglobulin A Nephropathy
- Atrasentan
- Placebo
- (no location specified)
Apr 27, 2023
Transthyretin Amyloid Cardiomyopathy Trial in New York (Empagliflozin)
Recruiting
- Transthyretin Amyloid Cardiomyopathy
-
New York, New YorkColumbia University Irving Medical Center / NewYork-Presbyterian
Mar 15, 2022
Blood Pressure, Salt; Excess, Diabete Type 2 Trial in Pisa (Hypersodic/Hyposodic diet)
Recruiting
- Blood Pressure
- +2 more
- Hypersodic/Hyposodic diet
-
Pisa, PI, ItalyAzienda Ospedaliero-Universitaria Pisana
Aug 23, 2023
Fatty Liver Disease Trial in Tainan (Canagliflozin 100mg)
Completed
- Fatty Liver Disease
- Canagliflozin 100mg
-
Tainan, TaiwanNational Cheng Kung University Hospital
Feb 28, 2023
Cystinuria Trial in San Francisco (Dapagliflozin)
Recruiting
- Cystinuria
-
San Francisco, CaliforniaUniversity of California, San Francisco
Oct 4, 2022
Heart Failure, Reduced Ejection Fraction Heart Failure Trial in Damanhur (Empagliflozin 10 MG, Dapagliflozin 10 MG)
Recruiting
- Heart Failure
- Reduced Ejection Fraction Heart Failure
- Empagliflozin 10 MG
- Dapagliflozin 10 MG
-
Damanhūr, Elbehairah, EgyptDamanhour Teaching Hospital, General Organization for Teaching H
Oct 3, 2023
GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Type 2
Recruiting
- Diabetes Mellitus, Type 2
- Myocardial Infarction
- PCI
-
Naples, ItalyCelestino Sardu
Aug 31, 2023
PCO Trial in Bani Suwayf (Dapagliflozin 5 MG, Metformin Hydrochloride 1000 MG, Dapagliflozin/Metformin)
Recruiting
- PCO
- Dapagliflozin 5 MG
- +2 more
-
Banī Suwayf, Beni Suef, EgyptBeni-suef university
Oct 26, 2022
Diabetes, Type 2, Endothelial Dysfunction Trial in Boston (Dapagliflozin, Placebo)
Recruiting
- Diabetes Mellitus, Type 2
- Endothelial Dysfunction
- Dapagliflozin
- Placebo
-
Boston, MassachusettsBU School of Medicine Evans 748
Jun 1, 2022
Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)
Not yet recruiting
- Atrial Fibrillation
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Rhythm control and anticoagulation
- (no location specified)
Aug 14, 2023
Diabetic Retinopathy Trial in Cairo (Dapagliflozin 10mg Tab plus another oral hypoglycemic agent, Two oral hypoglycemic agents
Recruiting
- Diabetic Retinopathy
- Dapagliflozin 10mg Tab plus another oral hypoglycemic agent
- Two oral hypoglycemic agents other than dapagliflozin
-
Cairo, EgyptInternal medicine and endocrinology department, Ain-shams univer
Jun 9, 2022